PD-L1 in non-small-cell lung cancer: the third target for immunotherapy-Reference-Cited by-同舟云学术

PD-L1 in non-small-cell lung cancer: the third target for immunotherapy

Published:2016-04 Issue:10030 Volume:387 Page:1795-1796
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Smit Egbert F,van den Heuvel Michel M

Publisher

Elsevier BV

Subject

General Medicine

Reference6 articles.

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum based chemotherapy;Shepherd;J Clin Oncol,2000

2. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study;Lynch;J Clin Oncol,2012

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma;Cancer Gene Therapy;2023-12-11

2. Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration;Cancer Letters;2023-11

3. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma;2023-09-29

4. Adverse childhood experiences (ACEs), cell-mediated immunity, and survival in the context of cancer;Brain, Behavior, and Immunity;2020-08

5. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer;Journal for ImmunoTherapy of Cancer;2019-08-27